Navigation Links
FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
Date:11/4/2010

INDIANAPOLIS, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain and chronic pain due to osteoarthritis. This is the fifth indication the FDA has approved for Cymbalta.

Cymbalta, which has been shown to significantly reduce chronic low back pain and chronic pain due to osteoarthritis, is a non-narcotic pain reliever that is meant to be taken once a day, every day by people with these pain conditions.

"People with chronic musculoskeletal pain often struggle to find a medication that works for them. The approval of Cymbalta for chronic musculoskeletal pain by the FDA gives doctors another option to help an underserved and suffering group of patients," said Michael Clark, M.D., MPH, director, Chronic Pain Treatment Program, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins Medical Institutions.

Although the exact way that Cymbalta works to reduce chronic musculoskeletal pain is unknown, it is believed that Cymbalta helps lessen pain by enhancing the body's natural pain suppressing system by increasing the activity of serotonin and norepinephrine in the brain and spinal cord.

In chronic musculoskeletal pain clinical studies, the most commonly observed adverse events (those occurring in at least 5 percent of study participants taking Cymbalta and at least twice the rate of placebo) in Cymbalta-treated patients with chronic low back pain were nausea, dry mouth, insomnia, sleepiness, constipation, dizziness and fatigue. The most commonly observed adverse events in Cymbalta-treated patients with chronic pain due to osteoarthritis were nausea, fatigue and constipation.

"It's important that p
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves New Indication for Afinitor
2. FDA Approves Teflaro for Bacterial Infections
3. FDA Approves Latuda to Treat Schizophrenia in Adults
4. FDA Approves Additional Medical Indication for Sprycel
5. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
6. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
7. FDA Approves Botox to Treat Chronic Migraine
8. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
9. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
10. FDA Approves Combination Contraceptive Containing a Folate
11. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... BEIJING , May 14 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... marketing and,sale of medical products in China , today reported ... . , (Logo: http://www.newscom.com/cgi-bin/prnh/20100422/CNTH001LOGO ), ... for the first quarter ended March 31, 2010 increased 5% to, ...
... BEIJING , May 14 /PRNewswire-Asia-FirstCall/ -- ... growing developer,manufacturer and seller of medicine and drugs in the ... for the first quarter,ended March 31, 2010 . , , ... -- Diluted EPS of $0.09, up 27% from first ...
Cached Medicine Technology:Dehaier Medical Systems Announces First Quarter Net Income Up 54% 2Dehaier Medical Systems Announces First Quarter Net Income Up 54% 3Dehaier Medical Systems Announces First Quarter Net Income Up 54% 4Dehaier Medical Systems Announces First Quarter Net Income Up 54% 5Dehaier Medical Systems Announces First Quarter Net Income Up 54% 6Dehaier Medical Systems Announces First Quarter Net Income Up 54% 7Dehaier Medical Systems Announces First Quarter Net Income Up 54% 8Dehaier Medical Systems Announces First Quarter Net Income Up 54% 9Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 2Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 3Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 4Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 5Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 6Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 7Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 8Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 9Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results 10
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Pharmaceuticals,Inc. (Nasdaq: CADX ), a biopharmaceutical company ... principally,for use in the hospital setting, today announced ... before the market opens on Tuesday, May 6,2008., ... and live webcast to,discuss the financial results and ...
... to Both Reduce Exacerbations ... and Improve Lung Function, ... and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone propionate 250 ... exacerbations in patients with chronic obstructive,pulmonary disease (COPD) who have ...
... Phase of NHLBI-Sponsored Study on Children,s Physical Activity in Child Care ... at Pediatric Academic Societies ... Annual Meeting, CINCINNATI, ... 3-6) are in child care centers, and growing concern over,childhood obesity has ...
... prolapse a tear or weakness in a womans pelvic ... the body runs in families, a new Saint Louis ... has had a hernia or prolapse two conditions that ... more likely to develop prolapse themselves, says Mary McLennan, M.D., ...
... April 30 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... radiology groups and hospitals throughout the United States,today ... appointed as an,independent member of the company,s Board ... change, the company has regained compliance with the ...
... FOREST, Ill., April 30 Hospira, Inc.,(NYSE: HSP ... announced that Thomas E. Werner, senior vice president,Finance, and ... Bank of America 2008 Health Care Conference on Wednesday, ... Vegas., The presentation is scheduled to begin at ...
Cached Medicine News:Health News:Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 2Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 3Health News:Flip Flops, Mulch and No Coat: Study Identifies Surprising Barriers to Outdoor Activity for Kids in Child-Care Centers 4Health News:Family history places women at risk of pelvic organ prolapse, SLU research finds 2Health News:NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors 2Health News:NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: